|
시장보고서
상품코드
1941512
페리틴 검사 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)Ferritin Testing Market Size, Share & Trends Analysis Report By Product (Instrument, Reagent, Kits), By Application (Anemia, Hemochromatosis, Lead Poisoning, Pregnancy), By End Use, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
페리틴 검사 시장 요약
세계의 페리틴 검사 시장 규모는 2025년에 9억 9,219만 달러로 추정되며, 2033년까지 16억 859만 달러에 달할 것으로 예측됩니다.
2026년부터 2033년까지 CAGR 6.52%로 성장할 것으로 예상됩니다. 철결핍성 빈혈, 혈색소 침착증 등 철분 과다증의 유병률 증가가 페리틴 검사의 수요를 견인하고 있습니다.
임산부 건강관리, 만성질환, 소아 환자에서 철분 모니터링의 중요성에 대한 인식이 높아지면서 수요가 증가하고 있습니다. 자동 분석기, 현장 검사 키트 등 진단 기술의 발전으로 접근성과 정확성이 향상되어 시장 성장을 더욱 촉진하고 있습니다. 또한, 예방의학에 대한 관심 증가와 신흥시장의 의료 인프라 확충이 맞물려 조기 진단과 효과적인 치료 관리를 위한 페리틴 검사의 도입을 뒷받침하고 있습니다.
기술 혁신으로 획기적인 POC(Point-of-Care) 진단 장비가 도입되면서 페리틴 검사는 크게 변화했습니다. 미세유체 종이 분석기(µPAD)와 종이 기반 전기화학 면역 센서는 페리틴 측정을 위한 휴대성, 비용 효율성, 신뢰성을 겸비한 획기적인 도구의 한 예입니다. 이러한 장비는 기존의 실험실 장비를 사용할 수 없는 자원 제약 환경에서 특히 유용하게 사용할 수 있습니다. 예를 들어, 마이크로 PAD는 모세관 전혈 샘플을 사용하여 페리틴 농도를 측정할 수 있어 원격지에서 신속한 선별 및 진단이 가능합니다. 이 혁신은 접근성 문제를 해결할 뿐만 아니라 의료진에게 실용적인 데이터를 제공함으로써 공중 보건 대책을 추진하는 데에도 기여합니다. QDx Instacheck과 같은 제품은 이러한 트렌드를 구현하고 있으며, 강력한 POC 진단 시스템을 제공함으로써 페리틴 검사를 병원이나 검사실에서 진료소, 나아가 환자 진료 현장 근처까지 확장하고 있습니다.
페리틴 검사 산업을 견인하는 또 다른 요인은 모자보건에 대한 관심의 증가입니다. 철결핍성 빈혈은 특히 중저소득 국가에서 임산부와 어린이의 발병률을 높이는 주요 원인이 되고 있습니다. 이러한 대상자의 페리틴 수치를 조기에 발견하는 것은 조산, 저체중아 출산, 소아 발달 지연과 같은 합병증 예방에 매우 중요합니다. 휴대용 페리틴 검사 장비의 보급으로 의료진은 철분 상태 모니터링을 정기적인 임산부 검진이나 소아 의료에 포함시켜 건강 상태를 개선할 수 있게 되었습니다. 예를 들어, 지방의 지역 보건 프로그램에서는 휴대용 진단 도구를 활용하여 위험에 처한 개인을 파악한 후 철분 보충이나 식단 개선과 같은 표적화된 개입을 시행할 수 있습니다.
페리틴 검사는 철분 결핍에 대응하는 것 외에도 철분 과잉과 관련된 만성질환 및 병태 관리에도 중요한 역할을 합니다. 혈색소 침착증, 간질환, 만성 신장질환 환자는 합병증 예방을 위해 정기적인 페리틴 수치 모니터링이 필요한 경우가 많습니다. 자동분석기, 면역측정법 등 첨단 진단기술의 도입으로 임상현장에서의 페리틴 검사의 정확성과 효율성이 향상되고 있습니다. 또한, 인공지능(AI) 및 머신러닝 알고리즘을 진단 시스템에 통합하여 데이터 해석의 정확도를 높이고 개인화된 치료 계획을 수립할 수 있습니다. 예를 들어, AI 기반 플랫폼은 다른 바이오마커와 함께 페리틴 검사 결과를 분석하여 환자의 철분 상태와 전신 건강 상태를 종합적으로 평가할 수 있습니다.
예방 의료 및 건강 증진에 대한 수요 증가도 페리틴 검사 산업에 새로운 기회를 창출하고 있습니다. 개인들이 자신의 건강 관리에 적극적으로 참여하면서 정기적인 건강 검진의 일환으로 철분 수치 선별 검사에 대한 관심이 높아지고 있습니다. 이러한 추세는 특히 선진국 시장에서 두드러지게 나타나고 있으며, 소비자들은 가정용 검사 키트와 원격의료 서비스를 이용할 수 있습니다. 각 업체들은 이러한 수요에 대응하기 위해 개인이 집에서 편안하게 건강 상태를 관리할 수 있는 사용하기 쉬운 진단 솔루션을 개발하고 있습니다. 예를 들어, 모세혈관 혈액 샘플을 사용하여 스마트폰 앱을 통해 결과를 제공하는 가정용 페리틴 검사 키트가 보급되고 있으며, 편리성과 실시간 인사이트를 제공하고 있습니다.
이러한 발전에도 불구하고, 특히 의료 서비스가 부족한 지역에서 페리틴 검사의 보급을 보장하기 위한 과제는 여전히 남아 있습니다. 고급 진단 시스템의 높은 비용과 페리틴 측정의 중요성에 대한 인식 부족이 시장 성장의 걸림돌로 작용하고 있습니다. 그러나 정부 및 비정부기구(NGO)의 철분 결핍 검진 및 치료 촉진 노력은 이러한 격차 해소에 기여하고 있습니다. 빈혈 예방에 초점을 맞춘 공중 보건 캠페인 등으로 인해 도시와 농촌 모두에서 페리틴 검사에 대한 인식이 높아져 수요가 증가하고 있습니다. 또한, 진단 기기 제조업체와 의료 서비스 제공자가 협력하여 자원이 제한된 환경에서도 저렴한 검사 솔루션을 제공하고 있습니다.
진단기술의 연구개발(R&D)에 대한 관심이 높아짐에 따라 페리틴 검사 산업이 더욱 확대될 것으로 예상됩니다. 각 업체들은 휴대성, 정확성, 사용 편의성을 겸비한 차세대 진단 도구 개발에 투자를 아끼지 않고 있습니다. 예를 들어, 바이오센서 기술과 나노소재의 발전으로 고감도, 고특이성의 페리틴 검사 장치 개발이 진행되고 있습니다. 이러한 혁신은 철 관련 질환을 조기에 발견하고 환자의 치료 결과를 개선함으로써 진단 분야를 혁신적으로 변화시킬 수 있는 잠재력을 가지고 있습니다. 또한, 클라우드 기반 플랫폼과 진단 장비의 통합으로 데이터 관리가 강화되어 원격 모니터링이 가능합니다. 이는 원격의료와 디지털 헬스 분야에서 특히 가치가 있습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 시장 변수, 동향 및 범위
제4장 제품 비즈니스 분석
제5장 용도별 비즈니스 분석
제6장 최종 용도별 비즈니스 분석
제7장 지역별 비즈니스 분석
제8장 경쟁 구도
KSM 26.03.13Ferritin Testing Market Summary
The global ferritin testing market size was estimated at USD 992.19 million in 2025 and is projected to reach USD 1,608.59 million by 2033, growing at a CAGR of 6.52% from 2026 to 2033. The rising prevalence of iron deficiency anemia and iron overload disorders such as hemochromatosis has driven the demand for ferritin testing.
Increased awareness of the importance of iron monitoring in maternal health, chronic diseases, and pediatric populations has boosted demand. Advancements in diagnostic technologies, such as automated analyzers and point-of-care testing kits, have enhanced accessibility and accuracy, further driving market growth. In addition, the growing focus on preventive healthcare, coupled with expanding healthcare infrastructure in emerging markets, supports the adoption of ferritin tests for early diagnosis and effective treatment management.
Technological advancements have revolutionized ferritin testing by introducing innovative point-of-care (POC) diagnostic devices. Microfluidic paper analytical devices (µPADs) and paper-based electrochemical immunosensors are examples of groundbreaking tools that offer portable, cost-effective, and reliable solutions for ferritin measurement. These devices are particularly beneficial in resource-limited settings, where traditional laboratory infrastructure may be unavailable. For instance, µPADs can use capillary whole blood samples to measure ferritin levels, enabling rapid screening and diagnosis in remote areas. This innovation not only addresses the challenges of accessibility but also facilitates public health interventions by providing actionable data for healthcare providers. Products like QDx Instacheck exemplify this trend, offering a powerful POC diagnostic system that extends ferritin testing beyond hospitals and laboratories to clinics and even near patient care sites.
Another driving factor in the ferritin testing industry is the increasing focus on maternal and child health. Iron deficiency anemia is a leading cause of morbidity among pregnant women and children, particularly in low- and middle-income countries. Early detection of ferritin levels in these populations is critical for preventing complications such as preterm birth, low birth weight, and developmental delays in children. The availability of portable ferritin testing devices allows healthcare providers to integrate iron status monitoring into routine antenatal and pediatric care, thereby improving health outcomes. For example, community health programs in rural areas can leverage portable diagnostic tools to identify at-risk individuals and implement targeted interventions, such as iron supplementation or dietary modifications.
In addition to addressing iron deficiency, ferritin testing plays a crucial role in managing chronic diseases and conditions associated with iron overload. Patients with hemochromatosis, liver disorders, or chronic kidney disease often require regular monitoring of ferritin levels to prevent complications. The adoption of advanced diagnostic technologies, such as automated analyzers and immunoassays, has enhanced the accuracy and efficiency of ferritin testing in clinical settings. Furthermore, the integration of artificial intelligence (AI) and machine learning algorithms into diagnostic systems has the potential to improve data interpretation and enable personalized treatment plans. For instance, AI-driven platforms can analyze ferritin test results in conjunction with other biomarkers to provide a comprehensive assessment of a patient's iron status and overall health.
The rising demand for preventive healthcare and wellness initiatives has also created opportunities in the ferritin testing industry. As individuals become more proactive about their health, there is a growing interest in routine screening for iron levels as part of general health check-ups. This trend is particularly evident in developed markets, where consumers can access home-based testing kits and telemedicine services. Companies are capitalizing on this demand by developing user-friendly diagnostic solutions that empower individuals to monitor their health from the comfort of their homes. For example, home-based ferritin testing kits that use capillary blood samples and provide results through smartphone apps are gaining popularity, offering convenience and real-time insights.
Despite these advancements, challenges remain in ensuring the widespread adoption of ferritin testing, particularly in underserved regions. The high cost of advanced diagnostic systems and limited awareness about the importance of ferritin measurement are barriers to market growth. However, initiatives by governments and non-governmental organizations (NGOs) to promote iron deficiency screening and treatment are helping to bridge this gap. Public health campaigns, such as those focused on anemia prevention, are creating awareness and driving demand for ferritin testing in both urban and rural areas. Additionally, partnerships between diagnostic companies and healthcare providers are facilitating the distribution of affordable testing solutions to resource-constrained settings.
The growing emphasis on research and development (R&D) in diagnostic technologies is expected to expand the ferritin testing industry further. Companies are investing in the development of next-generation diagnostic tools that combine portability, accuracy, and ease of use. For instance, advancements in biosensor technology and nanomaterials are paving the way for highly sensitive and specific ferritin testing devices. These innovations have the potential to transform the diagnostic landscape by enabling early detection of iron-related disorders and improving patient outcomes. Moreover, the integration of cloud-based platforms with diagnostic devices is enhancing data management and enabling remote monitoring, which is particularly valuable in the context of telemedicine and digital health.
Global Ferritin Testing Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global ferritin testing market report based on product, application, end use, and region:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Instrument
- Reagent
- Kits
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Anemia
- Hemochromatosis
- Lead Poisoning
- Pregnancy
- Others
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Diagnostic Laboratories
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Information Procurement
- 1.2. Information or Data Analysis
- 1.3. Market Scope & Segment Definition
- 1.4. Market Model
- 1.4.1. Market Study, By Company Market Share
- 1.4.2. Regional Analysis
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Segmentation and Scope
- 3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
- 3.3. Market Trends and Outlook
- 3.4. Market Dynamics
- 3.5. Market Restraint Analysis
- 3.6. Business Environment Analysis
- 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
- 3.6.2. Porter's Five Forces Analysis
Chapter 4. Product Business Analysis
- 4.1. Ferritin Testing Market: Product Movement Analysis
- 4.2. Instrument
- 4.2.1. Instrument Market, 2021 - 2033 (USD Million)
- 4.3. Reagent
- 4.3.1. Reagent Market, 2021 - 2033 (USD Million)
- 4.4. Kits
- 4.4.1. Kits Market, 2021 - 2033 (USD Million)
Chapter 5. Application Business Analysis
- 5.1. Ferritin Testing Market: Application Movement Analysis
- 5.2. Anemia
- 5.2.1. Anemia Market, 2021 - 2033 (USD Million)
- 5.3. Hemochromatosis
- 5.3.1. Hemochromatosis Market, 2021 - 2033 (USD Million)
- 5.4. Lead Poisoning
- 5.4.1. Lead Poisoning Market, 2021 - 2033 (USD Million)
- 5.5. Pregnancy
- 5.5.1. Pregnancy Market, 2021 - 2033 (USD Million)
- 5.6. Others
- 5.6.1. Others Market, 2021 - 2033 (USD Million)
Chapter 6. End-use Business Analysis
- 6.1. Ferritin Testing Market: End-use Movement Analysis
- 6.2. Hospitals
- 6.2.1. Hospitals Market, 2021 - 2033 (USD Million)
- 6.3. Diagnostic Laboratories
- 6.3.1. Diagnostic Laboratories Unit Market, 2021 - 2033 (USD Million)
Chapter 7. Regional Business Analysis
- 7.1. Ferritin Testing Market Share, By Region, 2025 & 2033
- 7.2. North America
- 7.2.1. North America Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.2.2. U.S.
- 7.2.2.1. Key Country Dynamics
- 7.2.2.2. Target Disease Prevalence
- 7.2.2.3. Competitive Scenario
- 7.2.2.4. Regulatory Framework
- 7.2.2.5. Reimbursement Scenario
- 7.2.2.6. U.S. Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.2.3. Canada
- 7.2.3.1. Key Country Dynamics
- 7.2.3.2. Target Disease Prevalence
- 7.2.3.3. Competitive Scenario
- 7.2.3.4. Regulatory Framework
- 7.2.3.5. Reimbursement Scenario
- 7.2.3.6. Canada Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.2.4. Mexico
- 7.2.4.1. Key Country Dynamics
- 7.2.4.2. Target Disease Prevalence
- 7.2.4.3. Competitive Scenario
- 7.2.4.4. Regulatory Framework
- 7.2.4.5. Reimbursement Scenario
- 7.2.4.6. Mexico Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.3. Europe
- 7.3.1. Europe Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.3.2. Germany
- 7.3.2.1. Key Country Dynamics
- 7.3.2.2. Target Disease Prevalence
- 7.3.2.3. Competitive Scenario
- 7.3.2.4. Regulatory Framework
- 7.3.2.5. Reimbursement Scenario
- 7.3.2.6. Germany Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.3.3. UK
- 7.3.3.1. Key Country Dynamics
- 7.3.3.2. Target Disease Prevalence
- 7.3.3.3. Competitive Scenario
- 7.3.3.4. Regulatory Framework
- 7.3.3.5. Reimbursement Scenario
- 7.3.3.6. UK Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.3.4. France
- 7.3.4.1. Key Country Dynamics
- 7.3.4.2. Target Disease Prevalence
- 7.3.4.3. Competitive Scenario
- 7.3.4.4. Regulatory Framework
- 7.3.4.5. Reimbursement Scenario
- 7.3.4.6. France Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.3.5. Italy
- 7.3.5.1. Key Country Dynamics
- 7.3.5.2. Target Disease Prevalence
- 7.3.5.3. Competitive Scenario
- 7.3.5.4. Regulatory Framework
- 7.3.5.5. Reimbursement Scenario
- 7.3.5.6. Italy Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.3.6. Spain
- 7.3.6.1. Key Country Dynamics
- 7.3.6.2. Target Disease Prevalence
- 7.3.6.3. Competitive Scenario
- 7.3.6.4. Regulatory Framework
- 7.3.6.5. Reimbursement Scenario
- 7.3.6.6. Spain Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.3.7. Denmark
- 7.3.7.1. Key Country Dynamics
- 7.3.7.2. Target Disease Prevalence
- 7.3.7.3. Competitive Scenario
- 7.3.7.4. Regulatory Framework
- 7.3.7.5. Reimbursement Scenario
- 7.3.7.6. Denmark Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.3.8. Sweden
- 7.3.8.1. Key Country Dynamics
- 7.3.8.2. Target Disease Prevalence
- 7.3.8.3. Competitive Scenario
- 7.3.8.4. Regulatory Framework
- 7.3.8.5. Reimbursement Scenario
- 7.3.8.6. Sweden Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.3.9. Norway
- 7.3.9.1. Key Country Dynamics
- 7.3.9.2. Target Disease Prevalence
- 7.3.9.3. Competitive Scenario
- 7.3.9.4. Regulatory Framework
- 7.3.9.5. Reimbursement Scenario
- 7.3.9.6. Norway Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.4.2. Japan
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Target Disease Prevalence
- 7.4.2.3. Competitive Scenario
- 7.4.2.4. Regulatory Framework
- 7.4.2.5. Reimbursement Scenario
- 7.4.2.6. Japan Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.4.3. China
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Target Disease Prevalence
- 7.4.3.3. Competitive Scenario
- 7.4.3.4. Regulatory Framework
- 7.4.3.5. Reimbursement Scenario
- 7.4.3.6. China Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.4.4. India
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Target Disease Prevalence
- 7.4.4.3. Competitive Scenario
- 7.4.4.4. Regulatory Framework
- 7.4.4.5. Reimbursement Scenario
- 7.4.4.6. India Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.4.5. South Korea
- 7.4.5.1. Key Country Dynamics
- 7.4.5.2. Target Disease Prevalence
- 7.4.5.3. Competitive Scenario
- 7.4.5.4. Regulatory Framework
- 7.4.5.5. Reimbursement Scenario
- 7.4.5.6. South Korea Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.4.6. Australia
- 7.4.6.1. Key Country Dynamics
- 7.4.6.2. Target Disease Prevalence
- 7.4.6.3. Competitive Scenario
- 7.4.6.4. Regulatory Framework
- 7.4.6.5. Reimbursement Scenario
- 7.4.6.6. Australia Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.4.7. Thailand
- 7.4.7.1. Key Country Dynamics
- 7.4.7.2. Target Disease Prevalence
- 7.4.7.3. Competitive Scenario
- 7.4.7.4. Regulatory Framework
- 7.4.7.5. Reimbursement Scenario
- 7.4.7.6. Thailand Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.5. Latin America
- 7.5.1. Latin America Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.5.2. Brazil
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Target Disease Prevalence
- 7.5.2.3. Competitive Scenario
- 7.5.2.4. Regulatory Framework
- 7.5.2.5. Reimbursement Scenario
- 7.5.2.6. Brazil Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.5.3. Argentina
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Target Disease Prevalence
- 7.5.3.3. Competitive Scenario
- 7.5.3.4. Regulatory Framework
- 7.5.3.5. Reimbursement Scenario
- 7.5.3.6. Argentina Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.6. MEA
- 7.6.1. MEA Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.6.2. South Africa
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Target Disease Prevalence
- 7.6.2.3. Competitive Scenario
- 7.6.2.4. Regulatory Framework
- 7.6.2.5. Reimbursement Scenario
- 7.6.2.6. South Africa Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.6.3. Saudi Arabia
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Target Disease Prevalence
- 7.6.3.3. Competitive Scenario
- 7.6.3.4. Regulatory Framework
- 7.6.3.5. Reimbursement Scenario
- 7.6.3.6. Saudi Arabia Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.6.4. UAE
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Target Disease Prevalence
- 7.6.4.3. Competitive Scenario
- 7.6.4.4. Regulatory Framework
- 7.6.4.5. Reimbursement Scenario
- 7.6.4.6. UAE Ferritin Testing Market, 2021 - 2033 (USD Million)
- 7.6.5. Kuwait
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Target Disease Prevalence
- 7.6.5.3. Competitive Scenario
- 7.6.5.4. Regulatory Framework
- 7.6.5.5. Reimbursement Scenario
- 7.6.5.6. Kuwait Ferritin Testing Market, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.2. Strategy Mapping
- 8.3. Company Market Share Analysis, 2025
- 8.4. Company Profiles/Listing
- 8.4.1. Eurolyser Diagnostica GmbH
- 8.4.1.1. Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Collection Site Benchmarking
- 8.4.1.4. Strategic Initiatives
- 8.4.2. Cortez Diagnostics Inc
- 8.4.2.1. Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Collection Site Benchmarking
- 8.4.2.4. Strategic Initiatives
- 8.4.3. Pointe Scientific, Inc.
- 8.4.3.1. Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Collection Site Benchmarking
- 8.4.3.4. Strategic Initiatives
- 8.4.4. Humankind Ventures Ltd
- 8.4.4.1. Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Collection Site Benchmarking
- 8.4.4.4. Strategic Initiatives
- 8.4.5. Aviva Systems Biology Corporation
- 8.4.5.1. Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Collection Site Benchmarking
- 8.4.5.4. Strategic Initiatives
- 8.4.6. bioMerieux S.A
- 8.4.6.1. Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Collection Site Benchmarking
- 8.4.6.4. Strategic Initiatives
- 8.4.7. Abnova Corporation
- 8.4.7.1. Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Collection Site Benchmarking
- 8.4.7.4. Strategic Initiatives
- 8.4.8. Cosmic Scientific Technologies
- 8.4.8.1. Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Collection Site Benchmarking
- 8.4.8.4. Strategic Initiatives
- 8.4.9. CTK Biotech, Inc
- 8.4.9.1. Overview
- 8.4.9.2. Financial Performance
- 8.4.9.3. Collection Site Benchmarking
- 8.4.9.4. Strategic Initiatives
- 8.4.10. Thermo Fisher Scientific Inc.
- 8.4.10.1. Overview
- 8.4.10.2. Financial Performance
- 8.4.10.3. Collection Site Benchmarking
- 8.4.10.4. Strategic Initiatives
- 8.4.1. Eurolyser Diagnostica GmbH
